Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$65.68+8.01%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PCVX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
PCVX — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-10-09
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Why it matters: The company says this study is needed before its planned BLA filing. It tests whether different vaccine batches match.
Watch forThe company starts and completes the planned study of batch-to-batch consistency. Results support the BLA filing.
Also watch forThe study finds a meaningful batch difference, or the company delays or drops the study.
Why it matters: This is an early test of Vaxcyte's Group A Strep vaccine. Safety and immune results will show if the program can advance.
Watch forThe company reports Phase 1 data in H2 2027, with no major safety issue and signs of an immune response.
Also watch forThe study finds a major safety issue, no useful immune response, or data after H2 2027.
Why it matters: These trials test VAX-31 with flu shots and in adults who had prior pneumococcal shots. Their results add key safety and immune data for the planned BLA.
Watch forBoth trials report in H1 2027, with safety and immune results that support the OPUS-1 findings.
Also watch forEither trial reports a safety concern, weak immune results, or results after H1 2027.
Why it matters: The infant study tests VAX-31 beyond its adult program. Positive results would add support for its use in children.
Supportive ifThe company reports primary-series and booster data by the end of H1 2027. There are no major safety issues, and immune responses are strong.
Worry ifThe study finds a major safety issue, weak immune responses, or data after H1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$149 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $377 loss on $10,000 · 3.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,795 loss on $10,000 · 28.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: OPUS-1 met its main goals, but two shared serotypes missed the set bar versus PCV21. Full results can clarify this gap.
Watch forFull OPUS-1 data show serotypes 3 and 12F meet the set noninferiority bar versus PCV21. Or, the data explain why the gap does not block the planned filing.
Also watch forFull data show a wider immune-response gap versus PCV21, or the company says it blocks its planned BLA.